Continuation and maintenance therapy in depression

British Medical Bulletin

Volumn 57, Issue , 2001, Pages 145-159

  Paykel, E S ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ARTICLE; COGNITIVE THERAPY; DEPRESSION; HUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; COGNITIVE THERAPY; DEPRESSIVE DISORDER; HUMANS; LITHIUM; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; TIME FACTORS;

EID: 0034963455     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/bmb/57.1.145     Document Type: Article

References (96)

1. Classification of affective disorders - The primary-secondary, the endogenous-reactive and the neurotic-psychotic dichotomies
2. Chronic depression
3. Recovery in major depressive disorder: Analysis with the life table and regression models
4. Relapse in major depressive disorder: Analysis with the life event table
5. Long-term outcome of episodes of major depression: Clinical and public health significance
6. Outcome of patients with chronic affective disorder: A five-year follow up
7. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up
8. The long-term outcome of depressive illness
9. The long-term outcome of Maudsley depressives
10. Future imperfect: The long-term outcome of depression
11. Remission and relapse in major depression: A two-year prospective follow up study
12. Residual symptoms after partial remission: An important outcome in depression
13. Conceptualisation and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse and recurrence
14. The place of antidepressants in long-term treatment
15. Tertiary prevention: Longer-term drug treatment in depression
16. Imipramine with electrical treatment in depression
17. The influence of antidepressant drugs on the response to ECT and on subsequent relapse rates
18. Successful lithium augmentation: How long should lithium be continued?
19. Optimal length of continuation therapy in depression: A prospective assessment during long-term fluoxetine treatment
20. Recognition and management of depression in general practice: Consensus statement
21. Maintenance treatment
22. An evaluation of continuation therapy with tricyclic antidepressants in depressive illness
23. Continuous drug therapy for major depressive episodes: How long should it be maintained?
24. Five year outcome for maintenance therapies in recurrent depression
25. Three year outcomes for maintenance therapies of recurrent depression
26. Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression
27. Amitriptyline, weight gain and carbohydrate craving: A side effect
28. Life events and social stress
29. The measurement of expressed emotion in the families of psychiatric patients
30. Levels of expressed emotion and relapse in depressed patients
31. Predictors of relapse in major depression
32. Do psychosocial factors influence outcome in severely depressed female psychiatric outpatients?
33. Life events, social support and marital relationships in the outcome of severe depression
34. Expressed emotion and depression: A longitudinal study
35. Course and outcome
36. Correlation between the dexamethasone suppression test in depressed patients and clinical response
37. Prophylactic lithium: Double blind discontinuation in manic-depressive and recurrent-depressive disorders
38. Prophylactic lithium in affective disorders
39. Lithium carbonate and imipramine in prevention of affective episodes
40. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders
41. Lithium prophylaxis of depression in bipolar I, bipolar II and unipolar patients
42. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness
43. Continuation therapy with lithium and amitriptyline in unipolar depressive illness: A randomised double-blind controlled trial
44. Lithium continuation therapy following electroconvulsive therapy
45. A double-blind comparison of lithium carbonate and maprotiline in the prophylaxis of the affective disorders
46. Mianserin and lithium in the prophylaxis of depression
47. Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: A randomised study
48. A 24 month study of unipolar subjects: A comparison between lilthium and fluvoxamine
49. Combination tricyclic antidepressant and lithium maintenance medication in unipolar and bipolar depressed patients
50. Response to maintenance therapy in bipolar illness: Effect of index episode
51. Prophylactic lithium carbonate with and without imipramine for bipolar 1 patients
52. Medication received by patients with depression following the acute episode: Adequacy and relation to outcome
53. Maintenance strategies for unipolar depression - An observational study of levels of treatment and recurrences
54. Medication treatment in first admission patients with psychotic affective disorders: Preliminary findings on research facility diagnostic agreement and rehospitalisation
55. Effectiveness in psychiatric care. 1: A cross-national study of the process of treatment and outcomes of major depressive disorder
56. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder
57. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders
58. Antidepressant withdrawal phenomena
59. Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition. Discontinuation Consensus Panel
60. Treatment of depression by drugs and psychotherapy
61. Treatment effects on the social adjustment of depressed outpatients
62. Effects of maintenance amitriptyline and psychotherapy on symptoms of depression
63. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: A randomised controlled trial in patients older than 59 years
64. Cognitive therapy and pharmacotherapy of depression: Sustained improvement over one year
65. A two year naturalistic follow up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both
66. Differential relapse following cognitive therapy and pharmacotherapy for depression
67. Depressed outpatients treated with cognitive therapy or pharmacotherapy
68. Cognitive-behavioural treatment of depressed inpatients: Six- and twelve-month follow-up
69. Course of depressive symptoms over follow-up
70. Cognitive behavioural treatment of residual symptoms in primary major depressive disorder
71. Four-year outcome for cognitive behavioural treatment of residual symptoms in major depression
72. Six year outcome for cognitive behavioural treatment of residual symptoms in major depression
73. Prevention of recurrent depression with cognitive behavioural therapy: Preliminary findings
74. Prevention of relapse by cognitive therapy in residual depression: A controlled trial
75. Effects of cognitive therapy on psychosocial symptoms and social functioning in residual depression
76. Continuation therapy with amitriptyline in depression
77. Maintenance therapy with amitriptyline: A controlled trial
78. Use of phenelzine in continuation therapy
79. Phenelzine for chronic depression: A study of continuation treatment
80. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression
81. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: A placebo-controlled 6 month study
82. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression
83. Rechutes de dépression unipolaire et efficacité de la maprotilinne
84. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients
85. How long should the elderly take antidepressants? A double blind placebo-controlled study of continuation/prophylaxis therapy with dothiepin
86. Maintenance therapy for chronic depression: A controlled clinical trial of desipramine
87. Continuation and maintenance treatment of major depression with monoamine oxidase inhibitor phenelzine: A double-blind placebo-controlled discontinuation study
88. Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: Likelihood of recurrence on discontinuation after 6 months' remission
89. The efficacy of zimeldine in preventing depressive episodes in recurrent major depressive disorders - A double blind placebo-controlled study
90. The prophylactic efficacy of fluoxetine in unipolar depression
91. Sertraline in the prevention of depression
92. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression
93. Dose efficacy of paroxetine in preventing depressive recurrences: A randomised, double-blind study
94. Fluvoxamine prevents recurrence of depression: Results of a long-term, double-blind, placebo-controlled study
95. Prevention of recurrent depressive episodes with milnacipran: Consequences on quality of life